Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 15/20 | 0.60 |
| ▸ | NOS1 | P29475 | 15/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.60 |
| ▸ | NOS2 | P35228 | 9/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.55 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4129205 | 0.95 | NOS3 (0.67) | NOS3NOS1SLC6A2NOS2KCNH2 | |
| SCHEMBL4134299 | 0.94 | NOS3 (0.66) | NOS3NOS1SLC6A2NOS2KCNH2 | |
| SCHEMBL12621069 | 0.94 | NOS3 (0.66) | NOS3NOS1SLC6A2NOS2KCNH2 | |
| SCHEMBL4134616 | 0.94 | NOS3 (0.66) | NOS3NOS1SLC6A2NOS2KCNH2 | |
| SCHEMBL1122042 | 0.94 | NOS3 (0.66) | NOS3NOS1SLC6A2NOS2KCNH2 | |
| SCHEMBL12367642 | 0.87 | NOS3 (0.59) | NOS3NOS1SLC6A2NOS2KCNH2 | |
| SCHEMBL13846440 | 0.86 | NOS3 (0.65) | NOS3NOS1SLC6A2NOS2KCNH2 | |
| SCHEMBL13849967 | 0.86 | NOS3 (0.65) | NOS3NOS1SLC6A2NOS2KCNH2 | |
| SCHEMBL1122075 | 0.86 | NOS3 (0.65) | NOS3NOS1SLC6A2NOS2KCNH2 | |
| SCHEMBL12305810 | 0.86 | NOS3 (0.65) | NOS3NOS1SLC6A2NOS2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101910157-B | Indole compounds and methods of treating visceral pain | NEURAXON INC | 2014-05-07 | — | — | CN | disclosed |
| US-8673909-B2 | Indole compounds and methods for treating visceral pain | NEURAXON, INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-8673909-B2 | Indole compounds and methods for treating visceral pain | NEURAXON, INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-8673909-B2 | Indole compounds and methods for treating visceral pain | NEURAXON, INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| CN-101910157-A | Indole compounds and methods of treating visceral pain | NEURAXON INC | 2010-12-08 | — | — | CN | disclosed |
| EP-2220074-A1 | 3,5-SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY | Neuraxon, INC. (CA) | 2010-08-25 | — | — | EP | disclosed |
| US-20090192157-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | NEURAXON, INC. (CA) | 2009-07-30 | — | — | US | disclosed |
| US-20090192157-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | NEURAXON, INC. (CA) | 2009-07-30 | — | — | US | disclosed |
| US-20090192157-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | NEURAXON, INC. (CA) | 2009-07-30 | — | — | US | disclosed |
| WO-2009062318-A1 | 3,5-SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009062319-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | NEURAXON, INC. (CA) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009062318-A1 | 3,5-SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131503-A1 | 3,5 - SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY | NEURAXON, INC (CA) | 2009-05-21 | — | — | US | disclosed |
| US-20090131503-A1 | 3,5 - SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY | NEURAXON, INC (CA) | 2009-05-21 | — | — | US | disclosed |
| US-20090131503-A1 | 3,5 - SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY | NEURAXON, INC (CA) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131503-A1 | 3,5 - SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY | SLC6A2, AANAT, NOS3 | NOS3 3/4885NOS1 5/4885SLC6A2 1/4885 |
| US-20090192157-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | TPH1, NOS1, IDO1 | NOS3 5/4885NOS1 2/4885SLC6A2 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.